Business Decision Support

Atebion BDS can assist clients in assessing portfolios and defining priorities in order to meet their strategic and operational objectives. We provide independent assessments or coordination of internal processes


If an Independent Assessment is deemed appropriate or helpful, Atebion BDS will provide any or all of the following;

  • A review of individual projects;
    • Core objectives and rationale, including how these relate to the market landscape
    • Review of market situation and competitive landscape (now and at time of launch)
    • Critical success factors and key claims required for clinical and commercial success
    • Sales estimates (WW and by region as required)
    • Sales and Marketing cost estimates (WW and by region as required)
    • Indicative S&M cost line for early-stage compounds (pre-TG2.5) and more detailed for projects post TG2.5
    • Key risk factors
    • Asset valuation by project
  • Comparison of asset valuation across the portfolio
    • Based on agreed technical, clinical and commercial criteria
  • Recommendations for prioritisation

Atebion BDS can help to streamline existing processes through creation of agreed templates for incorporation into Portfolio Review databases, for example;

  • Creation of agreed portfolio review timelines and processes
  • Creation of Project Executive Summary reports
  • Core Information templates by Project
  • Asset valuation tools (for individual assessment and enabling project by project comparison)
  • Project Progress report templates

Atebion BDS can coordinate the internal process if required, working with cross functional teams as appropriate. Alternatively, Atebion BDS can represent the commercial arm of a cross-functional team.

We have benefited from Ian’s support in a variety of areas since our first meeting 4yrs ago. He has offered invaluable advice and guidance on the strategic direction we needed to follow to make our drug programme more attractive to regulators, investors and licensees. With his advice, the company re-focused its efforts towards new orphan indications, enabling earlier entry into the clinic and a stronger value proposition. Ian offers an unusually varied skill base – he has been able to guide us strategically towards more commercially oriented end-points as well as advising on technical aspects within our drug development programmes, providing Company valuations and business development support He has a can-do team-oriented attitude and always delivers to time and quality. He is open, honest and has a high degree of professionalism. I trust and value his input and would strongly recommend him.

CEO: Emerging BioTech, US & Spain